GSK3B and cystic fibrosis: Taken together, the altered phenotype in CF PDEs centered around TGF-β-mediated inhibition of PTEN signaling, activation of PTEN downstream target AKT, and WNT activation likely through AKT-mediated inhibition of GSK3B.